Alanco Technologies

Alanco Technologies is a public holding company that has historically operated across diverse sectors, including wireless asset management (RFID) and environmental services. While the company previously provided RFID tracking solutions for the healthcare and correctional markets through its StarVision subsidiary, it sold those operations in 2011. In late 2023, Alanco Technologies signaled a strategic pivot into the biotechnology sector by entering into a Letter of Intent to merge with Nuvothera, a company focused on naturally-derived products for chronic inflammatory diseases. However, this merger agreement was terminated in early 2024, leaving Alanco as a public shell company seeking new strategic acquisitions. The company currently maintains no active proprietary drug pipeline but remains a public vehicle for potential future life science transactions.